Zhu H, Xue X, Wang E, et al
Each new study adds to the picture that injectable GLP-1 receptor agonists do not transfer into breast milk in meaningful amounts
The underlying pathogenesis seems to be related to an inflammatory response to foreign microcapsules due to a potential deficiency of enzymes needed to break down the poly-(d,l-lactide- co -glycolide) material into lactic and glycolic acid [58,59,60]
Just two weeks later, on 1 April 2026, the FDA approved Foundayo, Eli Lillys brand name for orforglipron, making it the first small-molecule, non-peptide oral GLP-1 receptor agonist approved for chronic weight management
There are no specific dietary restrictions required while taking tirzepatide